Every 10-Q that Nanoviricides (NNVC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NNVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NNVC filings page.
NanoViricides, Inc. reported continued operating losses in its quarter and nine months ended March 31, 2026, while advancing its broad-spectrum antiviral NV‑387. Net loss was $1,989,333 for the quarter and $5,995,110 for the nine months, driven by $6,060,077 in operating expenses.
The company had cash and cash equivalents of $3,213,256 and total assets of $10,219,004, against total liabilities of $1,065,407 and an accumulated deficit of $154,836,971. Management states there is substantial doubt about its ability to continue as a going concern, as existing cash and a $3,000,000 related-party credit line are not expected to fund operations for 12 months.
To support liquidity, NanoViricides raised approximately $1,909,000 net via an at-the-market offering and $5,403,981 net through a Registered Direct Offering and concurrent private placement of warrants. As of May 14, 2026, there were about 21,647,000 common shares outstanding and 7,147,720 warrants outstanding.
NV‑387 completed a Phase I safety and tolerability trial in healthy subjects with no reported adverse events and was granted U.S. FDA Orphan Drug Designation on April 27, 2026 for the treatment of Measles, positioning it for potential orphan-focused development paths.
NanoViricides, Inc. reported a net loss of $4.0 million for the six months ended December 31, 2025, improving from a $5.2 million loss a year earlier as operating expenses declined. The company remains a clinical-stage antiviral developer with no revenue to date.
Cash and cash equivalents rose to $5.2 million from $1.6 million at June 30, 2025, driven by equity financings and a $6.0 million registered direct and private placement transaction, leaving stockholders’ equity at $11.1 million. However, management states that existing cash and an undrawn $3.0 million related-party credit line are not sufficient to fund planned operations for at least 12 months, and they conclude that substantial doubt exists about the company’s ability to continue as a going concern.
The lead broad-spectrum antiviral candidate NV-387 completed a Phase I safety and tolerability trial in healthy subjects with no reported adverse events, and the company is preparing Phase II studies, including for MPox and viral respiratory infections. NanoViricides is also pursuing orphan drug designations in the United States for NV-387 in Measles, MPox, and Smallpox while continuing development of its herpes-focused NV-HHV-1 program and maintaining extensive license arrangements with related-party TheraCour Pharma for multiple viral indications.
NanoViricides, Inc. filed its quarterly results for the period ended September 30, 2025, reporting a net loss of $1.79 million, improved from $3.13 million a year ago, as operating expenses fell to $1.80 million. Cash and cash equivalents were $1.13 million, with total assets of $8.36 million and current liabilities of $1.18 million.
Management stated that, despite raising $1.25 million via at‑the‑market sales during the quarter, and approximately $6 million in a registered direct offering completed on November 12, 2025 (plus additional ATM proceeds), there is substantial doubt about the Company’s ability to continue as a going concern. The Company also has access to a $3 million related‑party line of credit, undrawn at quarter‑end. Shares outstanding were 17,556,079 as of September 30, 2025; approximately 17,997,000 were outstanding as of November 14, 2025.
Operationally, the company highlighted progress for lead antiviral NV‑387, including completion of a Phase I safety trial and a final approval from DRC’s ACOREP in late October 2025 to start a Phase II MPox study, subject to conditions.